普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察

发布时间：2018-10-26 10:21

【摘要】：目的:探讨普罗布考联合瑞舒伐他汀治疗血管性痴呆(VD)的有效性和安全性。方法:采用回顾性研究法,收集2013年5月-2015年2月在我院神经内科治疗的88例VD患者的临床资料,按治疗方案不同分为观察组和对照组,各44例。两组患者均给予控制血压和血糖、抗凝等常规治疗;在此基础上,对照组患者于每日睡前口服瑞舒伐他汀钙片20 mg;观察组患者在对照组治疗基础上餐后口服普罗布考片0.5 g,bid。两组患者均连续治疗3个月。比较两组患者治疗前后简易智能状态检测量表(MMSE)和日常生活能力量表(ADL)评分,血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、IL-1β、超氧化物歧化酶(SOD)和丙二醛(MDA)水平,以及不良反应发生情况。结果:治疗前,两组患者上述指标比较,差异均无统计学意义(P0.05)。治疗后,两组患者MMSE和ADL评分、血清SOD水平均较治疗前明显升高,血清TC、TG、LDL-C、CRP、TNF-α、IL-6、IL-1β、MDA水平均较治疗前明显降低,差异均有统计学意义(P0.05);且观察组患者上述指标均明显优于对照组,差异有统计学意义(P0.05)。两组患者HDL-C水平在治疗前后及组间比较,差异均无统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:普罗布考联合瑞舒伐他汀较单用瑞舒伐他汀更能有效降低VD患者的血脂、血清炎症因子和氧化应激指标水平,提高患者的认知功能和生活质量,且安全性较好。
[Abstract]:Objective: to investigate the efficacy and safety of probucol combined with rosuvastatin in the treatment of vascular dementia (VD). Methods: the clinical data of 88 patients with VD who were treated in our hospital from May 2013 to February 2015 were collected by retrospective study. According to different treatment schemes, they were divided into observation group and control group, each with 44 cases. Patients in both groups were given routine treatment such as controlling blood pressure, blood glucose and anticoagulant therapy, and the control group took rosuvastatin calcium tablets daily for 20 mg; before bedtime. The patients in the observation group took probucol 0.5 g bid after meal on the basis of treatment in the control group. The patients in both groups were treated continuously for 3 months. The mean mental state (MMSE) and activity of daily living (ADL) (ADL) scores were compared between the two groups before and after treatment. Serum total cholesterol (TC),) triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C) was measured. The levels of HDL-C), C reactive protein (CRP), tumor necrosis factor 伪 (TNF- 伪), interleukin 6 (IL-6), IL-1 尾, superoxide dismutase (SOD) and malondialdehyde (MDA) were measured. And the occurrence of adverse reactions. Results: before treatment, there was no significant difference between the two groups (P0.05). After treatment, the MMSE, ADL scores, serum SOD levels and serum TC,TG,LDL-C,CRP,TNF- 伪, IL-6,IL-1 尾, MDA levels in the two groups were significantly higher than those before treatment, and the serum TC,TG,LDL-C,CRP,TNF- 伪, IL-6,IL-1 尾 and MDA levels were significantly lower than those before treatment. The difference was statistically significant (P0.05). The above indexes in the observation group were significantly better than those in the control group, the difference was statistically significant (P0.05). There was no significant difference in HDL-C levels between the two groups before and after treatment (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: probucol combined with rosuvastatin can effectively reduce the levels of blood lipid, serum inflammatory factors and oxidative stress in patients with VD, improve their cognitive function and quality of life, and the safety is better.
【作者单位】：四川省医学科学院/四川省人民医院神经内科;
【分类号】：R741.05

【相似文献】